Log In Sign up
The largest database of trusted experimental protocols

Sch772984

Manufactured by MedChemExpress
Visit Supplier
Sourced in United States

SCH772984 is a laboratory reagent produced by MedChemExpress. It functions as an ATP-competitive inhibitor with selectivity for the ERK1/2 kinases. The product is intended for research use only.

Automatically generated - may contain errors

Lab products found in correlation

Ly294002, by MedChemExpress (5 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (5 mentions) Sb203580, by MedChemExpress (4 mentions) Afatinib, by Selleck Chemicals (4 mentions) Trametinib, by MedChemExpress (4 mentions) Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (4 mentions) Sp600125, by MedChemExpress (3 mentions) Erlotinib, by Selleck Chemicals (3 mentions) Lapatinib, by Selleck Chemicals (3 mentions) Gefitinib, by Selleck Chemicals (3 mentions) Amg510, by MedChemExpress (3 mentions) 5 aza 2 deoxycytidine dac, by Merck Group (3 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (3 mentions) Selumetinib, by Thermo Fisher Scientific (2 mentions) Nocodazol, by Merck Group (2 mentions) Ly3009120, by Selleck Chemicals (2 mentions) Shp099, by Selleck Chemicals (2 mentions) Cp 724714, by Merck Group (2 mentions) Epidermal growth factor (egf), by Thermo Fisher Scientific (2 mentions) Ro 3306, by Bio-Techne (2 mentions)

38 protocols using sch772984

1

Combinatorial Treatment of HCC Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
PI3K inhibitor LY294002, ERK1/2 inhibitor SCH772984, JNK inhibitor SP600125, p38 inhibitor SB203580, capmatinib and defactinib were purchased from MedChemExpress. The agents were used under the standard protocols. The HCC cells were pretreated with PI3K inhibitor LY294002 (10 μM), ERK1/2 inhibitor SCH772984 (10 μM), JNK inhibitor SP600125 (10 μM), or p38 inhibitor SB203580 (10 μM) for 1 h. defactinib was orally administered at a dose of 25 mg/kg twice a day, capmatinib was orally administered at a dose of 10 mg/kg/day. The treatment began on the seventh day after the establishment of the animal model and lasted eight weeks.
Zhang T., Wang Y., Xie M., Ji X., Luo X., Chen X., Zhang B., Liu D., Feng Y., Sun M., Huang W, & Xia L. (2022). HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET. Journal of Experimental & Clinical Cancer Research : CR, 41, 275.
+ Open protocol
+ Expand
2

Cell Viability Assay with SCH772984

Check if the same lab product or an alternative is used in the 5 most similar protocols
The cells were seeded (0.5–1×104) onto a 96-well culture plate for 12, 24, or 72 h with or without the drug to determine the number of living cells. Cell viability was evaluated using CCK8 assay. SCH772984 (MedChem Express) was reconstituted following the manufacturer’s recommendations and used at the indicated doses. Absorbance was measured at the absorbance of color (450 nm) by using a microplate absorbance reader.
Qiu D., Zhu Y, & Cong Z. (2020). YAP Triggers Bladder Cancer Proliferation by Affecting the MAPK Pathway. Cancer Management and Research, 12, 12205-12214.
+ Open protocol
+ Expand
3

Inhibitors and Activators of Key Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
The ERK inhibitor U0126 and the Src inhibitor dasatinib were purchased from Tocris Bioscience (Minneapolis, MN, USA). The ERK inhibitor SCH772984, AKT inhibitor LY294002, YAP inhibitor verteporfin, and YAP activator XMU-MP-1, were purchased from MedChemExpress (Monmouth Junction, NJ, USA). Hypoxia-mimetic CoCl2 was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Chang H.A., Ou Yang R.Z., Su J.M., Nguyen T.M., Sung J.M., Tang M.J, & Chiu W.T. (2023). YAP nuclear translocation induced by HIF-1α prevents DNA damage under hypoxic conditions. Cell Death Discovery, 9, 385.
+ Open protocol
+ Expand
4

Assessing Kinase Inhibitor Efficacy

Check if the same lab product or an alternative is used in the 5 most similar protocols
EGF was from Invitrogen; selumetinib, afatinib, lapatinib, lapatinib, gefitinib, erlotinib, SHP099 and LY3009120 were from SelleckChem; SCH772984 was from MedChem Express; PMA, nocodazol and CP-724714 were from Sigma-Aldrich; RO-3306 was from Tocris Bioscience; AMG-510 was from MedChemExpress.
Ponsioen B., Post J.B., des Amorie J.R., Laskaris D., van Ineveld R.L., Kersten S., Bertotti A., Sassi F., Sipieter F., Cappe B., Mertens S., Verlaan-Klink I., Boj S.F., Vries R.G., Rehmann H., Vandenabeele P., Riquet F.B., Trusolino L., Bos J.L, & Snippert H.J. (2021). Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signaling. Nature cell biology, 23(4), 377-390.
+ Open protocol
+ Expand
5

Investigating Autophagy and Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against mTOR (7C10) rabbit mAb (catalog 2983), phospho-mTOR (Ser2448) antibody (catalog 2971), p70 S6K antibody (catalog 9202), phospho-p70 S6K (Thr389) antibody (catalog 9205), AMPKα (D5A2) rabbit mAb (catalog 5831), phospho-AMPKα (Thr172) (40H9) rabbit mAb (catalog 2535), Atg5 (D5F5U) rabbit mAb (catalog 12994), Beclin 1 (D40C5) rabbit mAb (catalog 3495), SQSTM1/p62 antibody (catalog 5114), Akt antibody (catalog 9272), phospho-Akt (Ser473) antibody (catalog 9271), p44/42 MAPK (Erk1/2) antibody (catalog 9102), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) rabbit mAb (catalog 4377), and LC3A/B (D3U4C) XP rabbit mAb (catalog 12741) were obtained from Cell Signaling Technologies. Antibody against PARP (catalog CY6850) was obtained from Abways Technology. Antibody against β-actin (catalog A5441) was from MilliporeSigma. Sertraline (catalog S6319), fluphenazine (catalog PHR1792), erlotinib (catalog CDS022564), chloroquine phosphate (catalog PHR1258), avertin (catalog T48402, 152463), and dimethyl sulfoxide (catalog D2650) were purchased from MilliporeSigma. SCH772984 (catalog HY-50846), rapamycin (catalog HY-10219), dorsomorphin (catalog HY-13418A), and bafilomycin A1 (catalog HY-100558) were obtained from MedChemExpress, and 3-MA (catalog S2767) and Z-VAD-FMK (catalog S7023) were obtained from Selleck. All compounds were dissolved in dimethyl sulfoxide.
Jiang X., Lu W., Shen X., Wang Q., Lv J., Liu M., Cheng F., Zhao Z, & Pang X. (2018). Repurposing sertraline sensitizes non–small cell lung cancer cells to erlotinib by inducing autophagy. JCI Insight, 3(11), e98921.
+ Open protocol
+ Expand
6

Methylation Regulation Analysis in HCC

Check if the same lab product or an alternative is used in the 5 most similar protocols
For methylation regulation analysis, HCC cell lines were split to low density (30% confluence) 12 h before treatment. Cells were treated with 5-Aza-2′-deoxycytidine (DAC, Sigma, St. Louis, MO, USA) at a concentration of 2 μM in the growth medium, which was exchanged every 24 h for a total of 96 h and cultured at 37 °C in a 5% CO2 incubator. At the end of the treatment period, cells were prepared for extraction of total RNA. To verify the role of TMEM176A in ERK signaling, SCH772984, an ERK inhibitor, was added to TMEM176A knocking down SNU387 and SNU475 cells at 1 μm and 4 μm for 24 h (MedChemExpress, Monmouth Junction, USA) [21 (link)].
Li H., Zhang M., Linghu E., Zhou F., Herman J.G., Hu L, & Guo M. (2018). Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma. Clinical Epigenetics, 10, 137.
+ Open protocol
+ Expand
7

PPAR-Mediated Transcriptional Regulation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
AML12 cells were transfected with PPRE X3-TK-Luc (200 ng/well), β-gal expression vector (200ng/ well), and pSG5 PPARα (200 ng/well) plus other expression vectors (200 ng/well) as indicated using polyethylenimine (Sigma-Aldrich). Then, after growth for 24 h, cells received treatment of WY14643 (5μmol/ L, MedChemExpress), trametinib (100nmol/L, MedChemExpress), SCH772984 (50 nmol/L, MedChemExpress), or IKK16 (1 μmol/L, MedChemExpress) for another 24 h. Luciferase activity was determined with luciferase reporter assay system (Promega, Madison, WI, USA). β-gal activity, as the control for transfection efficiency, was measured by a kit (Mairybio Biological, Beijing, China). Results were averaged over three biological replicates.
Li Y., Chen M., Zhou Y., Tang C., Zhang W., Zhong Y., Chen Y., Zhou H, & Sheng L. (2020). NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease. Theranostics, 10(8), 3579-3593.
+ Open protocol
+ Expand
8

Cell Viability Assay: MTT Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell viability assay using MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (BioChemica, Applichem GmbH, Darmstadt, Germany) was performed. A total of 3000 MV3 cells were seeded as triplicates at a total volume of 90 µL per well of 96-well plates (Sarstedt AG) either coated with COL1 or left uncoated. After an incubation of 24 h, cells were treated with pathway inhibitors (tanzisertib, SCH772984, or trametinib) (MedChemExpress LLC, Monmouth Junction, Houston, TX, USA) as well as a dilution series of doxorubicin or mitoxantrone (10−4.5 to 10−8.5 M). After an incubation of 72 h, a MTT solution (20 µL, 5 mg/mL) was added for 1 h at 37 °C and 5% CO2. After removing the supernatant, formazan was solubilized in 200 µL of DMSO (Carl Roth GmbH, Karlsruhe, Germany). Plates were analyzed using a plate reader (Thermo Multiscan EX, Thermo, Schwerte, Germany) at 570 nm, with background subtraction at 690 nm. Data were normalized to DPBS as 100% viability.
Pfeifer V., Weber H., Wang Y., Schlesinger M., Gorzelanny C, & Bendas G. (2023). Exostosin 1 Knockdown Induces Chemoresistance in MV3 Melanoma Cells by Upregulating JNK and MEK/ERK Signaling. International Journal of Molecular Sciences, 24(6), 5452.
+ Open protocol
+ Expand
9

Signaling Pathway Inhibitor Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The CXCR4 inhibitor AMD3100 (HY-10046), ERK inhibitor SCH772984 (HY-50846), PI3K inhibitor LY294002 (HY-10108), mTOR inhibitor rapamycin (HY-10219), PKC inhibitor GO6983 (HY-13689) and PKA inhibitor H89 dihydrochloride (HY-15979A) were purchased from MedChemExpress (USA). Recombinant human CXCL12 protein was purchased from Bio-Techne (350-NS-010, R&D Systems, MN, USA). All the agents were used according to the manufacturer's instructions.
Detailed descriptions of all other materials and methods can be found in the online Supplementary Materials.
Feng W., Huang W., Chen J., Qiao C., Liu D., Ji X., Xie M., Zhang T., Wang Y., Sun M., Tian D., Fan D., Nie Y., Wu K, & Xia L. (2021). CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3. Theranostics, 11(6), 2612-2633.
+ Open protocol
+ Expand
10

HUVEC Culture and Stimulation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human umbilical vein endothelial cells (HUVEC) were purchased from Lonza and used for experiments at passage 4–8. Complete classic medium kit with culture boost and attachment factor (CSC, #4 Z0-500) was obtained from Cell Systems. EBM-2 medium (#CC3156) was from Lonza. Pen/Strep (100X) was from Thermo Fisher. Fetal bovine serum (FBS) and trypsin/EDTA were from HyClone. Recombinant human VEGF-165 (#293-VE-010/CF) was from R&D Systems. Human Scg3 (#16012-H08H) was from Sino Biological. PD98059 (#HY-12028) and SCH772984 (#HY-50846) were from MedChem Express.
Tang F., Pacheco M.T., Chen P., Liang D, & Li W. (2017). Secretogranin III promotes angiogenesis through MEK/ERK signaling pathway. Biochemical and biophysical research communications, 495(1), 781-786.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!